SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
SALT LAKE CITY - Co-Diagnostics, Inc. (NASDAQ:CODX) announced Monday that the Australian Patent Office has granted the company its first patent for its point-of-care PCR testing platform. The microcap ...
LONDON--(BUSINESS WIRE)--Medical and consumer genetics testing innovator and Imperial College London spin-out, DnaNudge, today announces that it has received approval from Ghana’s Food and Drugs ...
SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, ...
Hosted on MSN
Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform
CEO Dwight H. Egan reported continued progress on the Co-DX PCR point-of-care platform, stating, "We remain on track to initiate clinical evaluations for all tests in our pipeline during 2025." Egan ...
A new biotechnology company in McKinney has ambitions to become the world’s first fully integrated platform for polymerase chain reaction (PCR) testing — the same technology behind a common COVID-19 ...
The Company intends to use the funds awarded by the National Institutes of Health for completion of its upper respiratory panel multiplex on Co-Dx PCR Home™ platform SALT LAKE CITY, July 13, 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results